Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: Kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes

Journal of Immunology

Volumn 192, Issue 4, 2014, Pages 1630-1640

  Heine, Shannon J ^a,b   Diaz McNair, Jovita ^a,b   Andar, Abhay U ^c   Drachenberg, Cinthia B ^b   Van De Verg, Lillian ^d   Walker, Richard ^d   Picking, Wendy L ^e   Pasetti, Marcela F ^a,d  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d PATH   (United States)

^e OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; ESCHERICHIA COLI ENTEROTOXIN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PROTEIN IPAB; PROTEIN IPAD; SHIGELLA VACCINE; TUMOR NECROSIS FACTOR ALPHA; TYPE III SECRETION SYSTEM PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BACTERIUM MUTANT; CELL ACTIVATION; CELL KINETICS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DERMIS; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG UPTAKE; ESCHERICHIA COLI; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; INFECTION PREVENTION; LANGERHANS CELL; LOW DRUG DOSE; MACROPHAGE MIGRATION; MICRONEEDLE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLOSIS; T LYMPHOCYTE;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; CELL MOVEMENT; CROSS PROTECTION; CYTOKINES; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; DYSENTERY, BACILLARY; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LANGERHANS CELLS; MACROPHAGES; MICE; MICE, INBRED BALB C; NEUTROPHILS; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLA VACCINES; VACCINES, SUBUNIT;

EID: 84896717543     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302743     Document Type: Article

References (48)

1. Kotloff, K. L., J. P. Nataro, W. C. Blackwelder, D. Nasrin, T. H. Farag, S. Panchalingam, Y. Wu, S. O. Sow, D. Sur, R. F. Breiman, et al. 2013. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, casecontrol study. Lancet 382: 209-222.
2. Lozano, R., M. Naghavi, K. Foreman, S. Lim, K. Shibuya, V. Aboyans, J. Abraham, T. Adair, R. Aggarwal, S. Y. Ahn, et al. 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. [Published erratum appears in 2013 Lancet 381: 628.] Lancet 380: 2095-2128.
3. Murray, C. J., T. Vos, R. Lozano, M. Naghavi, A. D. Flaxman, C. Michaud, M. Ezzati, K. Shibuya, J. A. Salomon, S. Abdalla, et al. 2012. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. [Published erratum appears in 2013 Lancet 381: 628.] Lancet 380: 2197-2223.
4. Levine, M. M. 2006. Enteric infections and the vaccines to counter them: future directions. Vaccine 24: 3865-3873.
5. Barry, E. M., M. F. Pasetti, M. B. Sztein, A. Fasano, K. L. Kotloff, and M. M. Levine. 2013. Progress and pitfalls in Shigella vaccine research. Nat. Rev. Gastroenterol. Hepatol. 10: 245-255.
6. Levine, M. M., K. L. Kotloff, E. M. Barry, M. F. Pasetti, and M. B. Sztein. 2007. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat. Rev. Microbiol. 5: 540-553.
7. Venkatesan, M. M., and R. T. Ranallo. 2006. Live-attenuated Shigella vaccines. Expert Rev. Vaccines 5: 669-686.
8. Kaminski, R. W., and E. V. Oaks. 2009. Inactivated and subunit vaccines to prevent shigellosis. Expert Rev. Vaccines 8: 1693-1704.
9. Picking, W. L., H. Nishioka, P. D. Hearn, M. A. Baxter, A. T. Harrington, A. Blocker, and W. D. Picking. 2005. IpaD of Shigella flexneri is independently required for regulation of Ipa protein secretion and efficient insertion of IpaB and IpaC into host membranes. Infect. Immun. 73: 1432-1440.
10. Marteyn, B., A. Gazi, and P. Sansonetti. 2012. Shigella: a model of virulence regulation in vivo. Gut Microbes 3: 104-120.
11. Robin, G., D. Cohen, N. Orr, I. Markus, R. Slepon, S. Ashkenazi, and Y. Keisari. 1997. Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection. J. Infect. Dis. 175: 1128-1133.
12. Oberhelman, R. A., D. J. Kopecko, E. Salazar-Lindo, E. Gotuzzo, J. M. Buysse, M. M. Venkatesan, A. Yi, C. Fernandez-Prada, M. Guzman, R. León-Barúa, et al. 1991. Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides. Infect. Immun. 59: 2341-2350.
13. Van de Verg, L. L., D. A. Herrington, J. Boslego, A. A. Lindberg, and M. M. Levine. 1992. Age-specific prevalence of serum antibodies to the invasion plasmid and lipopolysaccharide antigens of Shigella species in Chilean and North American populations. J. Infect. Dis. 166: 158-161.
14. Wahid, R., J. K. Simon, W. L. Picking, K. L. Kotloff, M. M. Levine, and M. B. Sztein. 2013. Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. Clin. Immunol. 148: 35-43.
15. Martinez-Becerra, F. J., J. M. Kissmann, J. Diaz-McNair, S. P. Choudhari, A. M. Quick, G. Mellado-Sanchez, J. D. Clements, M. F. Pasetti, and W. L. Picking. 2012. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect. Immun. 80: 1222-1231.
16. Heine, S. J., J. Diaz-McNair, F. J. Martinez-Becerra, S. P. Choudhari, J. D. Clements, W. L. Picking, and M. F. Pasetti. 2013. Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. Vaccine 31: 2919-2929.
17. Qadri, F., T. R. Bhuiyan, D. A. Sack, and A. M. Svennerholm. 2013. Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine 31: 452-460.
18. Pasetti, M. F., J. K. Simon, M. B. Sztein, and M. M. Levine. 2011. Immunology of gut mucosal vaccines. Immunol. Rev. 239: 125-148.
19. Kim, Y. C., C. Jarrahian, D. Zehrung, S. Mitragotri, andM. R. Prausnitz. 2012. Delivery systems for intradermal vaccination. Curr. Top. Microbiol. Immunol. 351: 77-112.
20. PATH. 2013. Intradermal delivery of vaccines: a review of the literature and the potential for development for use in low- and middle-income countries.
21. Nelson, K. S., J. M. Janssen, S. B. Troy, and Y. Maldonado. 2012. Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine 30: 121-125.
22. Sanofi Pasteur. 2009. Intanza®/ID Flu®, first intradermal influenza vaccine, approved in the European Union [Press Release]. Available at: http://www.sanofipasteur.com/sanofi-pasteur4/ImageServlet?imageCode= 25356&siteCode=SP-CORP4. Accessed: September 10, 2013
23. Centers for Disease Control and Prevention. 2013. Intradermal influenza (flu) vaccination [Questions & answers]. Available at: http://www.cdc.gov/ flu/protect/vaccine/qa-intradermal-vaccine.htm. Accessed: September 10, 2013.
24. Hickling, J. K., K. R. Jones, M. Friede, D. Zehrung, D. Chen, and D. Kristensen. 2011. Intradermal delivery of vaccines: potential benefits and current challenges. Bull. World Health Organ. 89: 221-226.
25. Kupper, T. S., and R. C. Fuhlbrigge. 2004. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 4: 211-222.
26. Summerton, N. A., R. W. Welch, L. Bondoc, H. H. Yang, B. Pleune, N. Ramachandran, A. M. Harris, D. Bland, W. J. Jackson, S. Park, et al. 2010. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 28: 1404-1411.
27. Espina, M., A. J. Olive, R. Kenjale, D. S. Moore, S. F. Ausar, R. W. Kaminski, E. V. Oaks, C. R. Middaugh, W. D. Picking, and W. L. Picking. 2006. IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri. Infect. Immun. 74: 4391-4400.
28. Mach, H., C. R. Middaugh, and R. V. Lewis. 1992. Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins. Anal. Biochem. 200: 74-80.
29. Roche, J. A., D. L. Ford-Speelman, L. W. Ru, A. L. Densmore, R. Roche, P. W. Reed, and R. J. Bloch. 2011. Physiological and histological changes in skeletal muscle following in vivo gene transfer by electroporation. Am. J. Physiol. Cell Physiol. 301: C1239-C1250.
30. Goldberg, D. S., H. Ghandehari, and P. W. Swaan. 2010. Cellular entry of G3.5 poly (amido amine) dendrimers by clathrin- and dynamin-dependent endocytosis promotes tight junctional opening in intestinal epithelia. Pharm. Res. 27: 1547-1557.
31. Van Damme, P., F. Oosterhuis-Kafeja, M. Van derWielen, Y. Almagor, O. Sharon, and Y. Levin. 2009. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27: 454-459.
32. Hung, I. F., Y. Levin, K. K. To, K. H. Chan, A. J. Zhang, P. Li, C. Li, T. Xu, T. Y. Wong, and K. Y. Yuen. 2012. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine 30: 6427-6435.
33. Coleman, B. L., A. J. McGeer, S. A. Halperin, J. M. Langley, Y. Shamout, A. Taddio, V. Shah, and S. A. McNeil. 2012. A randomized control trial comparing immunogenicity, safety, and preference for self-versus nurse-administered intradermal influenza vaccine. Vaccine 30: 6287-6293.
34. Palucka, K., J. Banchereau, and I. Mellman. 2010. Designing vaccines based on biology of human dendritic cell subsets. Immunity 33: 464-478.
35. Liard, C., S. Munier, A. Joulin-Giet, O. Bonduelle, S. Hadam, D. Duffy, A. Vogt, B. Verrier, and B. Combadière. 2012. Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses. J. Invest. Dermatol. 132: 615-625.
36. Rath, T., T. T. Kuo, K. Baker, S. W. Qiao, K. Kobayashi, M. Yoshida, D. Roopenian, E. Fiebiger, W. I. Lencer, and R. S. Blumberg. 2013. The immunologic functions of the neonatal Fc receptor for IgG. J. Clin. Immunol. 33 (Suppl. 1): S9-S17.
37. Robbins, J. B., C. Chu, and R. Schneerson. 1992. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin. Infect. Dis. 15: 346-361.
38. Robbins, J. B., R. Schneerson, and S. C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171: 1387-1398.
39. Phalipon, A., M. Kaufmann, P. Michetti, J. M. Cavaillon, M. Huerre, P. Sansonetti, and J. P. Kraehenbuhl. 1995. Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis. J. Exp. Med. 182: 769-778.
40. Klechevsky, E., R. Morita, M. Liu, Y. Cao, S. Coquery, L. Thompson-Snipes, F. Briere, D. Chaussabel, G. Zurawski, A. K. Palucka, et al. 2008. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 29: 497-510.
41. Way, S. S., A. C. Borczuk, and M. B. Goldberg. 1999. Thymic independence of adaptive immunity to the intracellular pathogen Shigella flexneri serotype 2a. Infect. Immun. 67: 3970-3979.
42. Raqib, R., A. Ljungdahl, A. A. Lindberg, U. Andersson, and J. Andersson. 1996. Local entrapment of interferon gamma in the recovery from Shigella dysenteriae type 1 infection. Gut 38: 328-336.
43. Raqib, R., A. Gustafsson, J. Andersson, and M. Bakhiet. 1997. A systemic downregulation of gamma interferon production is associated with acute shigellosis. Infect. Immun. 65: 5338-5341.
44. van de Verg, L. L., C. P. Mallett, H. H. Collins, T. Larsen, C. Hammack, and T. L. Hale. 1995. Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection. Infect. Immun. 63: 1947-1954.
45. Sellge, G., J. G. Magalhaes, C. Konradt, J. H. Fritz, W. Salgado-Pabon, G. Eberl, A. Bandeira, J. P. Di Santo, P. J. Sansonetti, and A. Phalipon. 2010. Th17 cells are the dominant T cell subtype primed by Shigella flexneri mediating protective immunity. J. Immunol. 184: 2076-2085.
46. Lewis, D. J., Z. Huo, S. Barnett, I. Kromann, R. Giemza, E. Galiza, M. Woodrow, B. Thierry-Carstensen, P. Andersen, D. Novicki, et al. 2009. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 4: e6999.
47. Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350: 896-903.
48. Walker, R. I. 2005. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine 23: 3369-3385.